Is Azitra, Inc. (AZTR) a Buy, Sell, or Hold?
AMEX : AZTR
Azitra, Inc.
$0.139 USD
$0.01 (4.67%)
- Volume
- 1.71M
- Average Volume
- 11.78M
- Market Capitalization
- $1.49M
- P/E Ratio
- -0.06
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.60
- Year Low
- $0.10
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.94
Company Overview
AMEX
Francisco D. Salva
Biotechnology
Healthcare
AZTR
13
US
USD
Liquidity Metrics
0.03
6.94
6.94
6.49
0.00
Sales & Valuation
-$
0.00
0.21
-0.14
-0.70
Profitability
-$2.25
-$10.96M
0.00%
0.00%
-251.51%
-97.42%
P/E Metrics
-0.06
0.00
0.00
Analyst Price Target & Rating
3/5
1 Analysts
%
Poll Results
About Azitra, Inc. (AMEX:AZTR) Stock
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. ... operates from its headquarters in Branford, Connecticut.
2026-07-15 10:10:00
ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a high value cosmetic ingredient Ex vivo data successfully showed controlled distribution of the rHDfilaggrin into the stratum granulosum in increased amounts over prior single dose experiments in human skin Single dose ex vivo experiments established improvements in elasticity and reduced the appearance of new fine lines and wrinkles in human skin BRANFORD, Conn.
2026-06-17 08:00:00
BRANFORD, Conn., June 17, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Francisco Salva, Chief Executive Officer of Azitra, has issued a Letter to Shareholders detailing the Company's strategic growth initiatives, recent accomplishments and outlook for 2026 and beyond.
Azitra, Inc. to Present at 2026 BIO International Convention
2026-06-16 17:28:00
/PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision
Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
2026-06-04 16:05:00
BRANFORD, Conn., June 4, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced its 2026 Annual Meeting, originally scheduled for and convened on June 4, 2026, has been adjourned until June 15, 2026, at 11:00 a.m.
Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting
2026-05-27 16:30:00
BRANFORD, Conn., May 27, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to convene its upcoming 2026 annual meeting of stockholders (the "2026 Annual Meeting") scheduled for June 4, 2026 at 11:00 a.m.
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
2026-05-13 08:30:00
BRANFORD, Conn., May 13, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2026, and provided a business update.
Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
2026-05-06 08:00:00
Patent offers broad protections for ATR-12, an engineered strain of S. epidermidis that expresses a fragment of human LEKTI protein ATR-12 is currently the subject of a Phase 1b trial for the treatment of Netherton syndrome BRANFORD, Conn.
2026-04-28 08:02:00
Preclinical data demonstrate ATR-01 delivers functional filaggrin, restoring skin barrier integrity and supporting advancement toward first-in-human studies BRANFORD, Conn., April 28, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the presentation of new preclinical data from its ATR-01 program at the 2026 Annual Meeting of the American Society of Gene & Cell Therapy ("ASGCT 2026").
Frequently Asked Questions
-
What is the current Azitra, Inc. (AZTR) stock price?
-
Azitra, Inc.(AMEX:AZTR) stock price is $0.139 in the last trading session. During the trading session, AZTR stock reached the peak price of $1.6 while $0.1 was the lowest point it dropped to. The percentage change in AZTR stock occurred in the recent session was 4.67% while the dollar amount for the price change in AZTR stock was $0.01.
-
AZTR's industry and sector of operation?
-
The AMEX listed AZTR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AZTR?
-
Francisco D. Salva | President, Chief Executive Officer & Director
Travis Whitfill | Co-Founder, Chief Operating Officer, Secretary & Director
Norman Staskey | Chief Financial Officer & Treasurer
|
| -
How many employees does AZTR have?
-
Number of AZTR employees currently stands at 13. AZTR operates from 21 Business Park Drive, Branford, CT 06405, US.
-
Link for AZTR official website?
-
Official Website of AZTR is: https://azitrainc.com
-
How do I contact AZTR?
-
AZTR could be contacted at phone #203 646 6446 and can also be accessed through its website. AZTR operates from 21 Business Park Drive, Branford, CT 06405, US.
-
How many shares of AZTR are traded daily?
-
The average number of AZTR shares traded daily for last 3 months was 11.78M.
-
What is the market cap of AZTR currently?
-
The market value of AZTR currently stands at $1.49M with its latest stock price at $0.139